» Articles » PMID: 35765945

PLCE1 is a Poor Prognostic Marker and May Promote Immune Escape from Osteosarcoma by the CD70-CD27 Signaling Pathway

Overview
Specialty General Medicine
Date 2022 Jun 29
PMID 35765945
Authors
Affiliations
Soon will be listed here.
Abstract

Phospholipase C epsilon 1 (PLCE1) is involved in the pathogenesis of many cancers. However, the biological role of PLCE1 in osteosarcoma (OS) is still poorly understood. The prognostic survival analysis was performed on the PLCE1gene in the TARGET data set and the differential expression of PLCE1 in OS tissue and normal bone tissue on the tissue chip was detected by immunohistochemistry. Spearman's rank correlation coefficient analysis was implemented to explore the relationship between PLCE1 and immune genes. Finally, PLCE1 was silenced to explore its biological function in OS cells. The results of tissue chip immunohistochemistry showed that PLCE1 expression in OS tissue was higher than in normal bone tissue. The survival curve of PLCE1 and its corresponding receiver operating characteristic curve (ROC) showed that PLCE1 had a significant effect on the survival status of patients with OS and that the prognosis of patients with high PLCE1 expression was relatively poor. Spearman's rank correlation coefficient analysis and qRT-PCR assays found that PLCE1 may promote immune escape from OS via CD70-CD27 signaling pathway. Silencing of PLCE1 causes the following biological behaviors of OS cells: it promotes apoptosis, inhibits proliferation of OS cells, and inhibits the ability of cell migration and invasion. PLCE1 is a poor prognostic marker and a potential key factor affecting the immune status of the OS tumor microenvironment.

Citing Articles

Genome-wide association analysis identify candidate genes for feed efficiency and growth traits in Wenchang chickens.

Cai K, Liu R, Wei L, Wang X, Cui H, Luo N BMC Genomics. 2024; 25(1):645.

PMID: 38943081 PMC: 11212279. DOI: 10.1186/s12864-024-10559-w.


Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment.

Yang M, Su Y, Xu K, Zheng H, Yuan Q, Cai Y J Orthop Surg Res. 2023; 18(1):787.

PMID: 37858131 PMC: 10588205. DOI: 10.1186/s13018-023-04286-3.


Identification and validation of novel biomarkers associated with immune infiltration for the diagnosis of osteosarcoma based on machine learning.

Ji Y, Lin Z, Li G, Tian X, Wu Y, Wan J Front Genet. 2023; 14:1136783.

PMID: 37732314 PMC: 10507254. DOI: 10.3389/fgene.2023.1136783.


Jun-APOE-LRP1 axis promotes tumor metastasis in colorectal cancer.

He L, Shi M, Ren S, Zhang J, Tian Y, Yang X Biomol Biomed. 2023; 23(6):1026-1037.

PMID: 37310025 PMC: 10655886. DOI: 10.17305/bb.2023.9248.

References
1.
Mou X, Li T, Wang J, Ali Z, Zhang Y, Chen Z . Genetic Variation of BCL2 (rs2279115), NEIL2 (rs804270), LTA (rs909253), PSCA (rs2294008) and PLCE1 (rs3765524, rs10509670) Genes and Their Correlation to Gastric Cancer Risk Based on Universal Tagged Arrays and Fe3O4 Magnetic Nanoparticles. J Biomed Nanotechnol. 2015; 11(11):2057-66. DOI: 10.1166/jbn.2015.2113. View

2.
Wei L, Shao M, Zhao Y, Zheng J, Chu J, Chang J . Functional role of PLCE1 intronic insertion variant associated with susceptibility to esophageal squamous cell carcinoma. Carcinogenesis. 2017; 39(2):191-201. DOI: 10.1093/carcin/bgx123. View

3.
Wang Q, Hanada K, Robbins P, Li Y, Yang J . Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res. 2012; 72(23):6119-29. PMC: 3513562. DOI: 10.1158/0008-5472.CAN-12-0588. View

4.
Hanley C, Mellone M, Ford K, Thirdborough S, Mellows T, Frampton S . Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. J Natl Cancer Inst. 2017; 110(1). PMC: 5903651. DOI: 10.1093/jnci/djx121. View

5.
Waters J, Pober J, Bradley J . Tumour necrosis factor and cancer. J Pathol. 2013; 230(3):241-8. DOI: 10.1002/path.4188. View